Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma
Rituximab (R) in combination with DHAP is a widely accepted salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). A common adverse effect of this protocol is renal toxicity which may result in treatment discontinuation. Assuming that a lower single dose of c...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
11 April 2016
|
| In: |
BMC cancer
Year: 2016, Jahrgang: 16 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-016-2289-y |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1186/s12885-016-2289-y
|
| Verfasserangaben: | K. Lisenko, F. McClanahan, T. Schöning, M.A. Schwarzbich, M. Cremer, T. Dittrich, A. D. Ho and M. Witzens-Harig |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1681526832 | ||
| 003 | DE-627 | ||
| 005 | 20240323101644.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191108s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-016-2289-y |2 doi | |
| 035 | |a (DE-627)1681526832 | ||
| 035 | |a (DE-599)KXP1681526832 | ||
| 035 | |a (OCoLC)1341250613 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kriegsmann, Katharina |d 1986- |e VerfasserIn |0 (DE-588)1049422449 |0 (DE-627)781924006 |0 (DE-576)40339774X |4 aut | |
| 245 | 1 | 0 | |a Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma |c K. Lisenko, F. McClanahan, T. Schöning, M.A. Schwarzbich, M. Cremer, T. Dittrich, A. D. Ho and M. Witzens-Harig |
| 264 | 1 | |c 11 April 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 08.11.2019 | ||
| 520 | |a Rituximab (R) in combination with DHAP is a widely accepted salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). A common adverse effect of this protocol is renal toxicity which may result in treatment discontinuation. Assuming that a lower single dose of cisplatin over several days would reduce renal toxicity, our institution has chosen to administer cisplatin in a dosage of 25 mg/m2 per day as a 3-h infusion over 4 consecutive days. | ||
| 700 | 1 | |a Schöning, Tilman |d 1972- |e VerfasserIn |0 (DE-588)140330836 |0 (DE-627)617702489 |0 (DE-576)316456705 |4 aut | |
| 700 | 1 | |a Schwarzbich, Mark-Alexander |d 1983- |e VerfasserIn |0 (DE-588)143268236 |0 (DE-627)64435867X |0 (DE-576)335999263 |4 aut | |
| 700 | 1 | |a Cremer, Martin |e VerfasserIn |0 (DE-588)1084363852 |0 (DE-627)848800796 |0 (DE-576)456316078 |4 aut | |
| 700 | 1 | |a Dittrich, Tobias |d 1986- |e VerfasserIn |0 (DE-588)1075743141 |0 (DE-627)833664085 |0 (DE-576)444611495 |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 700 | 1 | |a Witzens-Harig, Mathias |e VerfasserIn |0 (DE-588)1050736516 |0 (DE-627)784812322 |0 (DE-576)404988970 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d London : BioMed Central, 2001 |g 16(2016) Artikel-Nummer 267, 7 Seiten |h Online-Ressource |w (DE-627)326643710 |w (DE-600)2041352-X |w (DE-576)107014645 |x 1471-2407 |7 nnas |a Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma |
| 773 | 1 | 8 | |g volume:16 |g year:2016 |a Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12885-016-2289-y |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20191108 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1050736516 |a Witzens-Harig, Mathias |m 1050736516:Witzens-Harig, Mathias |d 910000 |d 910100 |e 910000PW1050736516 |e 910100PW1050736516 |k 0/910000/ |k 1/910000/910100/ |p 8 |y j | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 998 | |g 1075743141 |a Dittrich, Tobias |m 1075743141:Dittrich, Tobias |d 910000 |d 910100 |e 910000PD1075743141 |e 910100PD1075743141 |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 998 | |g 1084363852 |a Cremer, Martin |m 1084363852:Cremer, Martin |d 910000 |d 910100 |e 910000PC1084363852 |e 910100PC1084363852 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 143268236 |a Schwarzbich, Mark-Alexander |m 143268236:Schwarzbich, Mark-Alexander |d 910000 |d 910100 |e 910000PS143268236 |e 910100PS143268236 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 140330836 |a Schöning, Tilman |m 140330836:Schöning, Tilman |d 910000 |d 910100 |e 910000PS140330836 |e 910100PS140330836 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 1049422449 |a Kriegsmann, Katharina |m 1049422449:Kriegsmann, Katharina |d 910000 |d 910100 |e 910000PK1049422449 |e 910100PK1049422449 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1681526832 |e 3538634963 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1186/s12885-016-2289-y"],"eki":["1681526832"]},"relHost":[{"origin":[{"publisherPlace":"London ; Berlin ; Heidelberg","dateIssuedKey":"2001","dateIssuedDisp":"2001-","publisher":"BioMed Central ; Springer"}],"title":[{"title_sort":"BMC cancer","title":"BMC cancer"}],"part":{"volume":"16","text":"16(2016) Artikel-Nummer 267, 7 Seiten","year":"2016"},"id":{"zdb":["2041352-X"],"issn":["1471-2407"],"eki":["326643710"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 22.05.20"],"recId":"326643710","disp":"Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphomaBMC cancer","language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.2001 -"]}],"note":["Gesehen am 08.11.2019"],"recId":"1681526832","origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"11 April 2016"}],"name":{"displayForm":["K. Lisenko, F. McClanahan, T. Schöning, M.A. Schwarzbich, M. Cremer, T. Dittrich, A. D. Ho and M. Witzens-Harig"]},"person":[{"family":"Kriegsmann","display":"Kriegsmann, Katharina","given":"Katharina","role":"aut"},{"family":"Schöning","display":"Schöning, Tilman","given":"Tilman","role":"aut"},{"family":"Schwarzbich","display":"Schwarzbich, Mark-Alexander","given":"Mark-Alexander","role":"aut"},{"role":"aut","given":"Martin","display":"Cremer, Martin","family":"Cremer"},{"given":"Tobias","display":"Dittrich, Tobias","family":"Dittrich","role":"aut"},{"role":"aut","family":"Ho","given":"Anthony Dick","display":"Ho, Anthony Dick"},{"display":"Witzens-Harig, Mathias","given":"Mathias","family":"Witzens-Harig","role":"aut"}],"language":["eng"],"title":[{"title":"Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma","title_sort":"Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma"}]} | ||
| SRT | |a KRIEGSMANNMINIMALREN1120 | ||